AstraZeneca将支付555M美元, 专用于Algen的AI-Help CRISPR针对免疫疾病的治疗。 AstraZeneca to pay $555M for exclusive rights to Algen’s AI-powered CRISPR therapies targeting immune diseases.

AstraZeneca同意与旧金山的Algen生物技术进行5.55亿美元的交易,利用AI和CRISPR技术开发基因编辑疗法,获得免疫系统疾病治疗的专属权利。 AstraZeneca has agreed to a $555 million deal with San Francisco-based Algen Biotechnologies to develop gene-editing therapies using AI and CRISPR technology, gaining exclusive rights to treatments for immune system diseases. 合作利用Algen的平台,该平台植根于诺贝尔奖获得者Jennifer Doudna的CRISPR研究,标志着AstraZeneca推动AI驱动的药物发现的一大步。 The collaboration leverages Algen’s platform, rooted in Nobel laureate Jennifer Doudna’s CRISPR research, and marks a major step in AstraZeneca’s push toward AI-driven drug discovery. 金融条款包括里程碑付款,公司股份在宣布后略有上升。 The financial terms include milestone payments, and the company’s shares rose slightly following the announcement.